

Autofluorescence imaging bronchoscopy as a novel approach to the management of tracheobronchopathia osteochondroplastica: a case report

Hiroaki Ihara^{1,2}, Ken Tajima^{1,2}, Hitomi Yoshikawa^{1,2}, Manabu Tajima^{1,2}, Norihiro Harada^{1,2}, Fumiyuki Takahashi^{1,2}, Toshimasa Uekusa³, Tetsutaro Nagaoka^{1,2}, Kazuhisa Takahashi^{1,2}

¹Department of Respiratory Medicine, ²Research Institute for Diseases of Old Ages, Juntendo University, Faculty of Medicine, Tokyo, Japan;

³Department of Pathology, Labor Health and Welfare Organization Kanto Rosai Hospital, Kawasaki, Japan

Correspondence to: Ken Tajima, MD, PhD. Department of Respiratory Medicine, Juntendo University, Faculty of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan. Email: tajiken@juntendo.ac.jp.

Abstract: Tracheobronchopathia osteochondroplastica (TO) is not only rare but also presents highly varied and unpredictable clinical manifestations. Consequently, the management and treatment strategies remain unclear. An accurate evaluation tool is important for the management of individual patients in the absence of standard guidelines. Although bronchoscopy is the gold standard for diagnosis, it cannot satisfactorily detect the treatment response and disease progression because subtle mucosal changes can go undetected. Therefore, improved techniques that can detect subtle mucosal changes associated with TO are desirable. Autofluorescence imaging bronchoscopy (AFI) is a recently introduced advanced endoscopic technology that can detect subtle mucosal changes with the aid of different colors. Here we report the first case, to the best of our knowledge, involving a 42-year-old man with TO in whom tracheal involvement was evaluated by AFI and detected as the appearance of a magenta color.

Keywords: Tracheobronchopathia osteochondroplastica (TO); autofluorescence imaging bronchoscopy (AFI); squamous metaplasia

Submitted Jun 30, 2016. Accepted for publication Aug 25, 2016.

doi: 10.21037/jtd.2016.10.48

View this article at: <http://dx.doi.org/10.21037/jtd.2016.10.48>

Introduction

Tracheobronchopathia osteochondroplastica (TO) is a rare disease characterized by the development of multiple, submucosal cartilaginous and osseous nodules (1-3). In general, rare diseases face significant challenges with regard to diagnosis and optimal management and treatment (4). The collection of adequate data pertaining to the clinical course of patients is necessary to provide useful information regarding response to treatment and disease progression. TO is not only rare but also presents highly varied and unpredictable clinical manifestations (1,2). Consequently, the management and treatment strategies remain unclear. Although there is less emphasis on the need for new

devices, an accurate evaluation tool is an important aspect of management. Bronchoscopy is the gold standard for TO diagnosis; however, it cannot satisfactorily assess subtle mucosal changes to determine the treatment response (5). Autofluorescence imaging bronchoscopy (AFI) is a recently introduced advanced endoscopic technology that can detect subtle mucosal changes with the aid of different colors (6). Here we report the AFI findings for a case involving a 42-year-old man with typical histopathological findings of TO.

Case presentation

A 42-year-old man with a 2-year history of chronic cough with sputum presented to our hospital with a complaint




Figure 1 Imaging and histopathological findings for a 42-year-old man with tracheobronchopathia osteochondroplastica. (A) An axial computed tomography image (soft tissue window) shows multiple calcified nodules in the anterior and lateral walls of the trachea; (B) bronchoscopy shows diffuse white nodules protruding into the tracheal lumen; (C) autofluorescence imaging bronchoscopy shows a magenta color covering the entire circumference of the trachea; (D,E) histopathological examination from biopsy of carina shows submucosal calcification and ossification with fatty bone marrow. (D) (HE; $\times 40$) Mucosal histopathology illustrates squamous metaplasia; (E) (HE; $\times 100$).

of hemoptysis since 2 weeks. Chronic sinusitis was the only significant component of his past medical history. He had no history of smoking. His physical examination was unremarkable. Routine blood investigations and immunological tests revealed normal findings. Staining for acid-fast bacilli was also negative. A pulmonary function test showed neither obstructive nor restrictive ventilation disorders. Flow-volume loop showed air-flow limitation which is expiratory plateau. Chest radiograph did not show any apparent findings. Computed tomography (CT) revealed multiple calcified nodules in the tracheobronchial lumen without posterior wall involvement (*Figure 1A*). Bronchoscopy revealed widespread bronchial wall edema and diffuse and irregular nodules protruding into the entire tracheal and two main bronchial lumens (*Figure 1B*). The lobar bronchi were spared. We subsequently performed AFI, which showed the entire circumference of the trachea in a magenta color (*Figure 1C*). The lobar and segmental airways appeared green. Histopathological examination

revealed squamous metaplasia with submucosal ossification, which was consistent with a diagnosis of TO (*Figure 1D,E*).

Discussion

TO is a rare disease described in 1857 by Wilkes *et al.* (1-3). While the accurate incidence remains unknown since it depends on each study population and symptom, it has been reported to be in the range from 0.02% to 3% (2,7). The development of CT and bronchoscopy techniques have improved the detection of this disease. However, the etiology remains unknown despite the increasing number of cases. Because of the lack of understanding about the etiological and pathogenetic mechanisms, there are no standard guidelines for TO management. Histopathological findings are varied and include squamous metaplasia, cartilage formation, ossification, and/or calcification in the submucosa (1-3). Although it is not clear whether squamous metaplasia is the first stage of the pathogenetic process, followed by cartilage formation

and ossification, or simply secondary to the chronicity of the condition, it remains the most common histopathological finding in TO patients (1,2).

AFI is a newly advanced bronchoscopy system that can detect weak autofluorescence signals from the bronchial mucosa (6). This technique can identify abnormal mucosa with the aid of different colors; pathological mucosa appears magenta while normal bronchial mucosa appears green. Although AFI has been developed to improve the early detection of malignant lesions and is widely accepted in oncological clinical practice, it exhibits high sensitivity but significantly low specificity. Several studies have shown that it can detect not only bronchogenic carcinoma *in situ* but also non-malignant lesions such as metaplasia (8-10). The ability of AFI to detect metaplasia can be useful for improving the visibility of pathological lesions in TO.

Currently, there is no consensus for the treatment of TO. Most treatments are not aimed at preventing disease progression but at palliation, and they vary from symptomatic management to bronchoscopic intervention for patients with severe airflow obstruction (7). Some studies have shown that inhaled corticosteroids are useful for patients with TO (5,11). Zhu *et al.* administered inhaled corticosteroids to eight patients (5) and reported a significant decrease in the number of lesions with cartilaginous nodules in two and the alleviation of symptoms to a certain extent in the remaining six, despite the absence of significant changes in bronchoscopy findings. These results suggest that evaluation using conventional bronchoscopy is insufficient for the detection of treatment responses. In our case, AFI showed the entire circumference of the trachea in a magenta color. On the other hand, the tracheal involvement was detected as irregular nodules protruding into the lumen without posterior wall by CT, suggesting that CT is also insufficient to detect subtle mucosal changes and to evaluate extent of the entire involvement of TO. Pulmonary Function Test, CT and conventional bronchoscopy could be enough to evaluate the significant disease progression. However, an accurate evaluation tool for predicting the response to treatment is thus required for the appropriate management of TO; AFI could be a suitable candidate for this purpose.

In conclusion, although conventional bronchoscopy is the gold standard for diagnosis for TO, our findings suggest that AFI is a suitable approach to the management and follow-up to develop the novel treatment of TO. To the best of our knowledge, this is the first report documenting the use of AFI for the detection of tracheal involvement in

TO. Although further studies are necessary to clarify the clinical utility of AFI, our report draws attention to the potential of this technique for appropriate management and follow-up.

Acknowledgements

The authors thank Editage for excellent English editorial assistance.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Informed Consent: Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images.

References

1. Leske V, Lazor R, Coetmeur D, et al. Tracheobronchopathia osteochondroplastica: a study of 41 patients. *Medicine (Baltimore)* 2001;80:378-90.
2. Abu-Hijleh M, Lee D, Braman SS. Tracheobronchopathia osteochondroplastica: a rare large airway disorder. *Lung* 2008;186:353-9.
3. Ulasli SS, Kupeli E. Tracheobronchopathia osteochondroplastica: a review of the literature. *Clin Respir J* 2015;9:386-91.
4. Groft SC. Rare diseases research: expanding collaborative translational research opportunities. *Chest* 2013;144:16-23.
5. Zhu Y, Wu N, Huang HD, et al. A clinical study of tracheobronchopathia osteochondroplastica: findings from a large Chinese cohort. *PLoS One* 2014;9:e102068.
6. He Q, Wang Q, Wu Q, et al. Value of autofluorescence imaging videobronchoscopy in detecting lung cancers and precancerous lesions: a review. *Respir Care* 2013;58:2150-9.
7. Jabbardarjani HR, Radpey B, Kharabian S, et al. Tracheobronchopathia osteochondroplastica: presentation of ten cases and review of the literature. *Lung* 2008;186:293-7.
8. Herth FJ, Eberhardt R, Anantham D, et al. Narrow-band imaging bronchoscopy increases the specificity of bronchoscopic early lung cancer detection. *J Thorac Oncol* 2009;4:1060-5.

9. Wang Y, Wang Q, Feng J, et al. Comparison of autofluorescence imaging bronchoscopy and white light bronchoscopy for detection of lung cancers and precancerous lesions. *Patient Prefer Adherence* 2013;7:621-31.
10. Nakanishi K, Ohsaki Y, Kurihara M, et al. Color auto-fluorescence from cancer lesions: improved detection of central type lung cancer. *Lung Cancer* 2007;58:214-9.
11. Zhang XB, Zeng HQ, Cai XY, et al. Tracheobronchopathia osteochondroplastica: a case report and literature review. *J Thorac Dis* 2013;5:E182-4.

Cite this article as: Ihara H, Tajima K, Yoshikawa H, Tajima M, Harada N, Takahashi F, Uekusa T, Nagaoka T, Takahashi K. Autofluorescence imaging bronchoscopy as a novel approach to the management of tracheobronchopathia osteochondroplastica: a case report. *J Thorac Dis* 2016;8(10):E1195-E1198. doi: 10.21037/jtd.2016.10.48